Sunday February 17, 2019 01:01

Heathcare Press Release : 16 Jun 2014


- Expertise in children patient care, digestive system and liver, and sports and orthopedic to be enhanced - Free bone marrow transplant offered to five children Samitivej celebrated its 35th anniversary with a commitment to enhancing customer

New Seahorse XFp Analyzer Makes Measuring Metabolism Affordable for Every Heathcare—16 Jun 14

Seahorse Bioscience , the world leader in metabolic analyzers and XF stress test kits for measuring cell metabolism, introduces the XFp Extracellular Flux Analyzer - an affordable extension to the XF product platform. This new, lower cost instrument will

Sanofi#s Lyxumia(R) (lixisenatide) Showed More Pronounced After-Test-Meal Blood Sugar Lowering Than Heathcare—16 Jun 14

Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that Lyxumia(R) (lixisenatide) met the primary endpoint in an 8-week head-to-head pharmacodynamic study versus liraglutide, showing a significantly more pronounced post-prandial (after-meal) glucose

Sanofi Announces Positive Phase 3 Results for Toujeo(R) (insulin glargine [rDNA origin] injection, Heathcare—16 Jun 14

- In EDITION JP I and II, investigational Toujeo(R)demonstrated similar blood sugar control with fewer night-time low blood sugar events over 6-month study period, vs. Lantus(R) - Sanofi (EURONEXT : SAN and NYSE : SNY) announced today full results from

Studies Show Investigational New Insulin Glargine Product from Lilly and Boehringer Ingelheim Heathcare—16 Jun 14

For the first time today, Eli Lilly and Company and Boehringer Ingelheim presented data showing that LY2963016, the alliance's investigational new insulin glargine product, has a similar safety and efficacy profile to currently marketed insulin glargine